EAM
NKTR icon

Eagle Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Eagle Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-53,651
Closed -$39.3M – 627
2018
Q2 		$39.3M Sell
53,651
-13,656
-20% -$15.7M 0.21% 179
2018
Q1 		$107M Sell
67,307
-432
-0.6% -$557K 0.58% 30
2017
Q4 		$61.6M Buy
+67,739
New +$40.1M 0.34% 101
2015
Q4 		– Sell
-38,677
Closed -$6.36M – 649
2015
Q3 		$6.36M Sell
38,677
-186
-0.5% -$32.9K 0.04% 382
2015
Q2 		$7.29M Sell
38,863
-251
-0.6% -$43.2K 0.04% 374
2015
Q1 		$6.45M Buy
+39,114
New +$8.04M 0.04% 396

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Eagle Asset Management's NKTR Position: Q3 2018 in Review

Eagle Asset Management sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 53,651 shares — an estimated $39.3M sold.

Eagle Asset Management first reported a position in NKTR in Q1 2015 and held it in 6 quarters. The position peaked at $107M in Q1 2018. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

  • Eagle Asset Management reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Eagle Asset Management sold 53,651 Nektar Therapeutics shares in Q3 2018, an estimated $39.3M.
  • Eagle Asset Management first reported a position in Nektar Therapeutics in Q1 2015 and held it in 6 quarters.
  • Eagle Asset Management's Nektar Therapeutics position peaked at $107M in Q1 2018.
  • 389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Eagle Asset Management's 13F filing for Q3 2018, filed 8 Nov 2018.